Matsushita, H.; Misumi, Y.; Masuda, T.; Okada, M.; Inoue, F.; Ueda, M.; Ando, Y.
Urinary Transthyretin as a Biomarker in ATTRv Val50Met Amyloidosis. Pathophysiology 2022, 29, 333-343.
https://doi.org/10.3390/pathophysiology29030025
AMA Style
Matsushita H, Misumi Y, Masuda T, Okada M, Inoue F, Ueda M, Ando Y.
Urinary Transthyretin as a Biomarker in ATTRv Val50Met Amyloidosis. Pathophysiology. 2022; 29(3):333-343.
https://doi.org/10.3390/pathophysiology29030025
Chicago/Turabian Style
Matsushita, Hiroaki, Yohei Misumi, Teruaki Masuda, Masamitsu Okada, Fumika Inoue, Mitsuharu Ueda, and Yukio Ando.
2022. "Urinary Transthyretin as a Biomarker in ATTRv Val50Met Amyloidosis" Pathophysiology 29, no. 3: 333-343.
https://doi.org/10.3390/pathophysiology29030025
APA Style
Matsushita, H., Misumi, Y., Masuda, T., Okada, M., Inoue, F., Ueda, M., & Ando, Y.
(2022). Urinary Transthyretin as a Biomarker in ATTRv Val50Met Amyloidosis. Pathophysiology, 29(3), 333-343.
https://doi.org/10.3390/pathophysiology29030025